PHVS
A small sale, a bigger headline
Pharvaris investors got a little insider-activity tea: director Schikan sold 7,100 shares across two days for roughly $213,000, at a weighted average price of $30.05 a share. On paper, that’s the kind of filing that can make traders sit up a little straighter.
But don’t overread the body language
Director sales can mean a lot of things: taxes, diversification, or just a human being trying to avoid having too many eggs in one biotech basket. A $213K sale is not exactly the corporate equivalent of jumping out a window.
What actually matters here
For Pharvaris, the real investor story is the pipeline and whatever comes next on the clinical or regulatory front. Insider sales are worth noting, sure — but they usually matter most when they’re part of a pattern or come alongside fresh bad news.
Big picture: this is the kind of filing that can nudge sentiment, but it’s not the thesis. The next catalyst will matter a lot more than one director’s sell order.